Research ExplorerPublicationsSelective elimination of immunosuppressive T cells in patien...

Selective elimination of immunosuppressive T cells in patients with multiple myeloma

Standard

Selective elimination of immunosuppressive T cells in patients with multiple myeloma. / Awwad, Mohamed H S; Mahmoud, Abdelrahman; Bruns, Heiko; Echchannaoui, Hakim; Kriegsmann, Katharina; Lutz, Raphael; Raab, Marc S; Bertsch, Uta; Munder, Markus; Jauch, Anna; Weisel, Katja; Maier, Bettina; Weinhold, Niels; Salwender, Hans Jürgen; Eckstein, Volker; Hänel, Mathias; Fenk, Roland; Dürig, Jan; Brors, Benedikt; Benner, Axel; Müller-Tidow, Carsten; Goldschmidt, Hartmut; Hundemer, Michael.

In: LEUKEMIA, Vol. 35, No. 9, 09.2021, p. 2602-2615.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Awwad, MHS, Mahmoud, A, Bruns, H, Echchannaoui, H, Kriegsmann, K, Lutz, R, Raab, MS, Bertsch, U, Munder, M, Jauch, A, Weisel, K, Maier, B, Weinhold, N, Salwender, HJ, Eckstein, V, Hänel, M, Fenk, R, Dürig, J, Brors, B, Benner, A, Müller-Tidow, C, Goldschmidt, H & Hundemer, M 2021, 'Selective elimination of immunosuppressive T cells in patients with multiple myeloma', LEUKEMIA, vol. 35, no. 9, pp. 2602-2615. https://doi.org/10.1038/s41375-021-01172-x

APA

Awwad, M. H. S., Mahmoud, A., Bruns, H., Echchannaoui, H., Kriegsmann, K., Lutz, R., Raab, M. S., Bertsch, U., Munder, M., Jauch, A., Weisel, K., Maier, B., Weinhold, N., Salwender, H. J., Eckstein, V., Hänel, M., Fenk, R., Dürig, J., Brors, B., ... Hundemer, M. (2021). Selective elimination of immunosuppressive T cells in patients with multiple myeloma. LEUKEMIA, 35(9), 2602-2615. https://doi.org/10.1038/s41375-021-01172-x

Vancouver

Awwad MHS, Mahmoud A, Bruns H, Echchannaoui H, Kriegsmann K, Lutz R et al. Selective elimination of immunosuppressive T cells in patients with multiple myeloma. LEUKEMIA. 2021 Sep;35(9):2602-2615. https://doi.org/10.1038/s41375-021-01172-x

Bibtex

@article{8d9eb5bb1c614da1b126b3695667f5ec,
title = "Selective elimination of immunosuppressive T cells in patients with multiple myeloma",
abstract = "Elimination of suppressive T cells may enable and enhance cancer immunotherapy. Here, we demonstrate that the cell membrane protein SLAMF7 was highly expressed on immunosuppressive CD8+CD28-CD57+ Tregs in multiple myeloma (MM). SLAMF7 expression associated with T cell exhaustion surface markers and exhaustion-related transcription factor signatures. T cells from patients with a high frequency of SLAMF7+CD8+ T cells exhibited decreased immunoreactivity towards the MART-1aa26-35*A27L antigen. A monoclonal anti-SLAMF7 antibody (elotuzumab) specifically depleted SLAMF7+CD8+ T cells in vitro and in vivo via macrophage-mediated antibody-dependent cellular phagocytosis (ADCP). Anti-SLAMF7 treatment of MM patients depleted suppressive T cells in peripheral blood. These data highlight SLAMF7 as a marker for suppressive CD8+ Treg and suggest that anti-SLAMF7 antibodies can be used to boost anti-tumoral immune responses in cancer patients.",
author = "Awwad, {Mohamed H S} and Abdelrahman Mahmoud and Heiko Bruns and Hakim Echchannaoui and Katharina Kriegsmann and Raphael Lutz and Raab, {Marc S} and Uta Bertsch and Markus Munder and Anna Jauch and Katja Weisel and Bettina Maier and Niels Weinhold and Salwender, {Hans J{\"u}rgen} and Volker Eckstein and Mathias H{\"a}nel and Roland Fenk and Jan D{\"u}rig and Benedikt Brors and Axel Benner and Carsten M{\"u}ller-Tidow and Hartmut Goldschmidt and Michael Hundemer",
year = "2021",
month = sep,
doi = "10.1038/s41375-021-01172-x",
language = "English",
volume = "35",
pages = "2602--2615",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "9",

}

RIS

TY - JOUR

T1 - Selective elimination of immunosuppressive T cells in patients with multiple myeloma

AU - Awwad, Mohamed H S

AU - Mahmoud, Abdelrahman

AU - Bruns, Heiko

AU - Echchannaoui, Hakim

AU - Kriegsmann, Katharina

AU - Lutz, Raphael

AU - Raab, Marc S

AU - Bertsch, Uta

AU - Munder, Markus

AU - Jauch, Anna

AU - Weisel, Katja

AU - Maier, Bettina

AU - Weinhold, Niels

AU - Salwender, Hans Jürgen

AU - Eckstein, Volker

AU - Hänel, Mathias

AU - Fenk, Roland

AU - Dürig, Jan

AU - Brors, Benedikt

AU - Benner, Axel

AU - Müller-Tidow, Carsten

AU - Goldschmidt, Hartmut

AU - Hundemer, Michael

PY - 2021/9

Y1 - 2021/9

N2 - Elimination of suppressive T cells may enable and enhance cancer immunotherapy. Here, we demonstrate that the cell membrane protein SLAMF7 was highly expressed on immunosuppressive CD8+CD28-CD57+ Tregs in multiple myeloma (MM). SLAMF7 expression associated with T cell exhaustion surface markers and exhaustion-related transcription factor signatures. T cells from patients with a high frequency of SLAMF7+CD8+ T cells exhibited decreased immunoreactivity towards the MART-1aa26-35*A27L antigen. A monoclonal anti-SLAMF7 antibody (elotuzumab) specifically depleted SLAMF7+CD8+ T cells in vitro and in vivo via macrophage-mediated antibody-dependent cellular phagocytosis (ADCP). Anti-SLAMF7 treatment of MM patients depleted suppressive T cells in peripheral blood. These data highlight SLAMF7 as a marker for suppressive CD8+ Treg and suggest that anti-SLAMF7 antibodies can be used to boost anti-tumoral immune responses in cancer patients.

AB - Elimination of suppressive T cells may enable and enhance cancer immunotherapy. Here, we demonstrate that the cell membrane protein SLAMF7 was highly expressed on immunosuppressive CD8+CD28-CD57+ Tregs in multiple myeloma (MM). SLAMF7 expression associated with T cell exhaustion surface markers and exhaustion-related transcription factor signatures. T cells from patients with a high frequency of SLAMF7+CD8+ T cells exhibited decreased immunoreactivity towards the MART-1aa26-35*A27L antigen. A monoclonal anti-SLAMF7 antibody (elotuzumab) specifically depleted SLAMF7+CD8+ T cells in vitro and in vivo via macrophage-mediated antibody-dependent cellular phagocytosis (ADCP). Anti-SLAMF7 treatment of MM patients depleted suppressive T cells in peripheral blood. These data highlight SLAMF7 as a marker for suppressive CD8+ Treg and suggest that anti-SLAMF7 antibodies can be used to boost anti-tumoral immune responses in cancer patients.

U2 - 10.1038/s41375-021-01172-x

DO - 10.1038/s41375-021-01172-x

M3 - SCORING: Journal article

C2 - 33597728

VL - 35

SP - 2602

EP - 2615

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 9

ER -